Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003 Jul;10(4):637-42.
doi: 10.1128/cdli.10.4.637-642.2003.

T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice

Affiliations
Comparative Study

T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice

C M Ausiello et al. Clin Diagn Lab Immunol. 2003 Jul.

Abstract

The relative value of antibodies and/or T-cell immune responses to Bordetella pertussis antigens in the immunity induced by acellular pertussis (aP) vaccines is still an open issue, probably due to the incomplete knowledge on the mechanisms of protective immunity to pertussis. The relevance of T-cell immune responses in protection from pertussis has been demonstrated in murine and human models of infection; thus, in this study, the ability of different vaccine preparations of three component (pertussis toxin, filamentous hemagglutinin, and pertactin) aP vaccines to induce T-cell responses was investigated in mice. All vaccine preparations examined passed the immunogenicity control test, based on antibody titer assessment, according to European Pharmacopoeia standards, and protected mice from B. pertussis intranasal challenge, but not all preparations were able to prime T cells to pertussis toxin, the specific B. pertussis antigen. In particular, one vaccine preparation was unable to induce proliferation and gamma interferon (IFN-gamma) production while the other two gave borderline results. The evaluation of T-cell responses to pertussis toxin antigen may provide information on the protective immunity induced by aP vaccines in animal models. Considering the critical role of the axis interleukin-12-IFN-gamma for protection from pertussis, our results suggest that testing the induction of a key protective cytokine such as IFN-gamma could be an additional tool for the evaluation of the immune response induced by aP vaccines.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Kinetics of B. pertussis clearance from lungs of intranasally challenged unvaccinated mice (NT) or mice vaccinated with aP vaccine preparations. Groups of CD1 (A) or BALB/c (B) mice were immunized i.p. at 0 and 3 weeks with one-half a human dose. Two weeks after completion of vaccination, mice were challenged with B. pertussis 18323 and CFU counts were performed on individual lung homogenates on the indicated days. Results are means ± SE (error bars) of viable B. pertussis counts from four mice per group at each time point. The results are representative of three experiments performed. The limit of detection of the assay was approximately log10 0.5 CFU per lung.
FIG. 2.
FIG. 2.
Lymphoproliferative response from immune CD1 (A) or BALB/c mice (B) was assessed at 15 (black bars) and 30 (grey bars) days after completion of the immunization schedule. Spleen cells (2 × 106/ml) were stimulated in vitro with the indicated antigens, as detailed in Materials and Methods. DNA synthesis was measured after 5 days by counting [3H]thymidine incorporation (counts per minute, 103). Results are mean values of SI obtained from three mice per group assessed individually and are representative of three experiments performed. The counts per minute (mean ± SE) of unstimulated cultures of spleen cells from the mice under study was 0.2 ± 0.06. The threshold of positive proliferative response is shown (SI = 4).

Similar articles

Cited by

References

    1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet i:955-960. - PubMed
    1. Ausiello, C. M., P. Sestili, C. Locardi, M. Logozzi, P. Rizza, E. Parlanti, L. Yang, A. Modica, A. Modesti, P. Musiani, and F. Belardelli. 1994. Defective response to T cell mitogens in mice injected with human immunodeficiency virus type 1-infected U937 cells. J. Gen. Virol. 75:2789-2794. - PubMed
    1. Ausiello, C. M., F. Urbani, A. la Sala, R. Lande, and A. Cassone. 1997. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65:2168-2174. - PMC - PubMed
    1. Ausiello, C. M., R. Lande, A. la Sala, F. Urbani, and A. Cassone. 1998. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J. Infect. Dis. 178:466-470. - PubMed
    1. Ausiello, C. M., R. Lande, F. Urbani, A. la Sala, P. Stefanelli, S. Salmaso, P. Mastrantonio, and A. Cassone. 1999. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67:4064-4071. - PMC - PubMed

Publication types

LinkOut - more resources